Cargando…
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
A novel coronavirus SARS-CoV-2, also called novel coronavirus 2019 (nCoV-19), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate...
Autores principales: | Ma, Chunlong, Sacco, Michael D., Hurst, Brett, Townsend, Julia A., Hu, Yanmei, Szeto, Tommy, Zhang, Xiujun, Tarbet, Bart, Marty, Michael T., Chen, Yu, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263507/ https://www.ncbi.nlm.nih.gov/pubmed/32511378 http://dx.doi.org/10.1101/2020.04.20.051581 |
Ejemplares similares
-
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020) -
Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
por: Hu, Yanmei, et al.
Publicado: (2020) -
Rational Design of Hybrid SARS-CoV-2 Main Protease
Inhibitors Guided by the Superimposed Cocrystal Structures with the
Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021) -
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020) -
Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)